IOBT vs. ANIX, DMAC, CLSD, ORMP, EBS, BTAI, ALLK, CLRB, ADAG, and PMVP
Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Anixa Biosciences (ANIX), DiaMedica Therapeutics (DMAC), Clearside Biomedical (CLSD), Oramed Pharmaceuticals (ORMP), Emergent BioSolutions (EBS), BioXcel Therapeutics (BTAI), Allakos (ALLK), Cellectar Biosciences (CLRB), Adagene (ADAG), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
IO Biotech (NASDAQ:IOBT) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
IO Biotech currently has a consensus price target of $8.33, suggesting a potential upside of 455.56%. Anixa Biosciences has a consensus price target of $12.00, suggesting a potential upside of 306.78%. Given IO Biotech's higher possible upside, equities analysts clearly believe IO Biotech is more favorable than Anixa Biosciences.
IO Biotech has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Anixa Biosciences has higher revenue and earnings than IO Biotech. Anixa Biosciences is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
Anixa Biosciences received 5 more outperform votes than IO Biotech when rated by MarketBeat users. However, 86.67% of users gave IO Biotech an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Anixa Biosciences' return on equity of -44.09% beat IO Biotech's return on equity.
54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by company insiders. Comparatively, 22.6% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Anixa Biosciences had 5 more articles in the media than IO Biotech. MarketBeat recorded 5 mentions for Anixa Biosciences and 0 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.98 beat Anixa Biosciences' score of 0.00 indicating that IO Biotech is being referred to more favorably in the media.
Summary
Anixa Biosciences beats IO Biotech on 9 of the 15 factors compared between the two stocks.
Get IO Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IO Biotech Competitors List
Related Companies and Tools
